China Medical System Holdings (HK:0867) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
China Medical System Holdings has announced the approval of its ruxolitinib phosphate cream for treating non-segmental vitiligo in Hong Kong. This novel treatment offers a new option for the approximately 75,000 vitiligo patients in Hong Kong, providing hope for those struggling with this chronic skin condition. The cream’s approval in various regions reflects its effectiveness and safety, as demonstrated in global clinical studies.
For further insights into HK:0867 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue